Denmark-based Novo Nordisk, makers of popular weight-loss drug Wegovy, has partnered with Emcure Pharmaceuticals to launch a weight-loss drug under the new brand, Poviztra. Like Wegovy, Poviztra is a semaglutide injection 2.4 mg to be used as an adjunct to a reduced calorie diet and physical activity for weight management and to reduce risks of major adverse cardiovascular issues in overweight or obese people. Advertisement

The companies announced Poviztra as the second brand of Wegovy, which was launched in India in 2025. One in three participants on Wegovy during clinical trials experienced weight loss of over 20 per cent.

Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra.

Jay Thyagarajan, Senior Vice President, Region AP

See Full Page